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CASE REPORT
Localizing an occult insulinoma by selective calcium arterial stimulation test:
first ever experience and a new dimension to diagnosis in Pakistan
Muhammad Owais Rashid1, Sumerah Jabeen2, Zareen Kiran3, Muhammad Khurram Minhas4, Muhammad Azeem5,
Najmul Islam6

Abstract
Insulinomas are rare, usually benign, solitary tumours
accounting for 60% of islet cell tumours. These tumours can
be diﬃcult to localize preoperatively due to their small size.
We present a challenging case of a 40 year old male with
frequent hypoglycaemic spells and endogenous
hypoglycaemia who presented as a diagnostic dilemma.
Patient had an occult insulinoma with inconclusive CT
Abdomen, MRI Abdomen and Octreotide scan. The ﬁnal
localization of the tumour was made by selective arterial
calcium stimulation testing (SCAT), done for the ﬁrst time
in Pakistan at Aga Khan University Hospital. This was
followed by successful distal pancreatectomy as localizd by
SACT yielding a well diﬀerentiated neuroendocrine tumour.
After surgery patient made a robust recovery with no
further hypoglycaemic symptoms. Hence successful
localization and management of occult insulinomas can be
challenging but can be achieved with the advent of newer
invasive modalities.
Keywords: Insulinomas, Hypoglycemia, Neuroendocrine
tumour
DOI: https://doi.org/10.5455/JPMA.19325

Introduction
The ﬁrst insulinoma was described by an orthopaedic
surgeon, Wider and colleagues in 1927, who experienced
frequent neuroglycopenic symptoms due to prolonged
fasting in the operating room.1 Insulinomas are rare
tumours with an incidence of 4 patients per 1 million /year
and accounts for 60% of islet cell tumours.2 They are
typically solitary tumours with 90% measuring less than 2
cm. They can also present as a benign multicentric disease
in patients with MEN 1.3 Due to their nonspeciﬁc,
occasionally bizarre symptoms these tumours can disguise
themselves with various neuropsychiatric conditions.4 An
occult insulinoma refers to a biochemically proven tumour
with an undetermined anatomical site before surgery.5
Their small size and diﬃcult preoperative localization along
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with nonspeciﬁc symptoms poses a diagnostic dilemma to
both the endocrinologists and surgeons. We present a case
of a 40 year old male with an occult insulinoma which after
a rigorous but futile imaging work up was ﬁnally localized
by Selective Calcium Arterial Stimulation Testing (SCAST),
done ﬁrst time in the history of Pakistan at Aga Khan
University Hospital. The consent of the patient was taken
prior to the manuscript writing.

Case
A 44 years old male known case of Hypothyroidism and
Hypertension presented to our endocrine clinic for the ﬁrst
time in June 2017 with episodes of recurrent sweating,
tremors, palpitations and generalized weakness. Patient
had these symptoms since last 2 years, observed during
fasting and relieved with food intake. During these
episodes his glucose went down to 35 -40mg/dl. He
combated with these spells of hypoglycaemia with instant
intake of choclates or sugar but did not seek any
professional help, due to excessive binge eating there was
a noticeable weight gain over this two year period. He had
a past history of pulmonary tuberculosis, treated few years
back. Family history was positive for diabetes,
hypertension, coronary artery disease and breast
carcinoma. His medication history included Olmesartan 40
mg OD and thyroxine 150 mcg OD. His multiple Serum
insulin, C- peptide, blood glucose done during 2 years
period were clearly suggestive of endogenous
hypoglycaemia. Patient had a BMI of 31.5kg/m2. Rest of his
physical examination was unremarkable. On the basis of
history and biochemical evaluation diagnosis of
Spontaneous hypoglycaemia secondary to endogenous
hyperinsulinaemic hypoglycaemia was made and patient
was advised CT scan abdomen (Pancreatic protocol) which
showed no pancreatic mass following which he was asked
to get MRI abdomen as next line investigation which also
did not reveal any pancreatic , hepatic or other masses. He
then underwent Somatostatin receptor scintigraphy with
no uptake in pancreas or liver. Patient was then planned for
Angiography of Coeliac and Superior mesenteric arteries
to look for tumour blush followed by Selective Calcium
Arterial Stimulation Testing (SCAST). This test involved the
femoral vein and artery cannulation with passage of a
sampling catheter to the right hepatic vein for sampling of
insulin and sequentially under ﬂuoroscopic guidance, a
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Table: Selective Calcium Arterial Stimulation Test Results.
Peripheral
Hepatic
Superior Mesenteric
Artery
Artery
Artery
0 sec:
Preinjection
Post 30 sec
Post 30 sec
Insulin 51.30
Insulin 48.80
Insulin 127.60
C-peptide 7.32 C-peptide 6.13
C-peptide 9.06
Post 60 sec
Post 60 sec
Insulin 55.30
Insulin 114.20
C-peptide 6.73
C-peptide 9.68
Post 90 sec
Post 90 sec
Insulin 63.40
Insulin 137.30
C-peptide 7.29
C-peptide 9.17
Post 120 sec
Post 120 sec
Insulin 63.40
Insulin 128.10
C-peptide 6.39
C-peptide 9.99
Post 180 sec
Post 180 sec
Insulin 59.80
Insulin 105.80
C-peptide 7.83
C-peptide 10.00

Gastroduodenal
Artery

Splenic
Artery

Post 30 sec
Insulin 139.10
C-peptide 12.90
Post 60 sec
Insulin 144.00
C-peptide 9.46
Post 90 sec
Insulin 127.60
C-peptide10.50
Post 120 sec
Insulin 51.30
C-peptide 7.32
Post 180 sec
Insulin 139.80
C-peptide 11.10

Post 30 sec
Insulin >300
C-peptide >20
Post 60 sec
Insulin >300
C-peptide 17.50
Post 90 sec
Insulin >300
C-peptide 12.30
Post 120 sec
Insulin 214.60
C-peptide 12.70
Post 180 sec
Insulin 149.80
C-peptide 12.20

catheter placed into the splenic, superior mesenteric and
gastroduodenal arteries to allow injection of calcium
gluconate into these arteries. A positive response was
deﬁned as at least a doubling of the insulin level after
injection calcium gluconate at more than one time point.
SCAST with venous sampling after calcium infusion
showed many folds increase in insulin, C peptide levels in
the splenic artery thus pointing towards the culprit lesion
in the body or tail of his pancreas (Table). Patient was then
referred to an experienced surgeon with the plan of a
pancreactic enucleation if the tumour could be localized
on peroperative ultrasound otherwise distal pancreactomy
being the second option. As the adenoma could not be
localized on peroperative ultrasound therefore he

Figure:

[A] Tumor cells showing round to oval, mildly pleomorphic nuclei with
characteristic finely stippled (salt and pepper) chromatin and
inconspicuouc nucleoli (H&E stain, 400x) [B] Tumour cell invading into
pancreatic acini (arrows) (H&E stain, 400x) [C] Perineural invasion
(arrows) (H&E stain, 400x) [D] Peripancreatic fat invasion (arrows)
(H&E stain, 400x)

underwent distal pancreatectomy. His histopathology
report showed a well diﬀerentiated neuroendocrine
tumour, grade 1 of distal pancreas with a size of 1.5X1.3
cm, Ki-67 index of <2% and stage of pT1,Nx (ﬁgure).
Postoperatively patient made good recovery with no
further hypoglycaemic episodes on follow up after one
month of his surgery and to date enjoying a healthy
life.
Patient was not evaluated for MEN1 as he denied any
other symptoms besides hypoglycaemia, also his
baseline work up did not show any clue of a
concomitant illness.

Discussion

Insulinomas are rare tumours but among the
functioning islet cell tumours are the most common.
Patients usually present with fasting hypoglycaemia
but upto 25% of such patients can also present with
post prandial hypoglycaemia. The hypoglycaemic
spells constitute both neuroglycopenic symptoms
including confusion, visual change and unusual behaviour
that may or may not be preceded by sympathoadrenal
symptoms which includes tremulousness, palpitations or
diaphoresis.6,7 The hypoglycaemia in insulinoma is
observed to be due to reduced hepatic glucose output
rather than an increased glucose utilization. In a study
conducted at Mayo clinic it was observed that it took a
median time of 1.5 years for a patient to report his
symptoms before a diagnosis of insulinoma was made.2
The biochemical diagnosis of insulinoma is established by
demonstrating raised serum insulin and C- peptide levels
during an episode of hypoglycaemia, but the diagnosis and
preoperative localization of these occult tumours is never
straight forward owing to the small size and sporadic
distribution, thus it remains a diagnostic challenge to the
endocrinologists, surgeons and the radiologists. Surgical
removal is the treatment of choice in insulinomas,
therefore it is imperative to localize these tumours
preoperatively as it not only helps in deciding the type of
surgery but also some of these tumours may not be
palpable at the time of surgery.
After biochemical conﬁrmation preoperative procedures
for tumour localization includes number of noninvasive
and invasive radiological investigations most of which are
operator dependent and require skills. These include
transabdominal ultrasonography (sensitivity 30%-61%), CT
(sensitivity 42%-78%), MRI Abdomen (sensitivity 20%100%), octreotide scan (sensitivity 78%-86%), Endoscopic
ultrasonography (sensitivity 80%), Selective Arterial
Calcium Stimulation Testing(SACST) with hepatic venous
sampling(sensitivity
90%),
and
intraoperative
J Pak Med Assoc
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bimanual

interpret the results correctly and manage the patient
appropriately.

Selective Arterial Calcium Stimulation Testing (SACST) is an
interventional radiological technique. John L. Doppman9
developed SACST after observing that intravenously
administered calcium stimulates insulin release from from
insulinoma, but not from normal beta cells . Placzkowski et
al. demonstrated a sensitivity for localization of upto 93 %
in patients who underwent this procedure in Mayo clinic
series.6

Although being done in diﬀerent countries this test was a
new milestone in the endocrine history of Pakistan as it was
the ﬁrst time ever that this invasive technique was
successfully attempted. Localizing the culprit insulin
producing tumour by SACST open new doors, providing
ground for other centers in Pakistan equipped with
interventional radiology to start performing this test where
diagnosing insulinoma remains a challenge pre operatively.

Literature review shows SACT to be superior to other non
invasive modalities with localization sensitivity of 87.5 to
90%.10 When compared with other invasive techniques like
EUS, the localization sensitivity of EUS is similar to SACT but
does not provide functional information with its speciﬁcity
being aﬀected when pancreatic nodularities are mistaken
for insulinomas. The short comings of the two procedures
are similar including invasiveness with lack of universal
availability and operator and centre dependence.11

Conclusion

ultrasonography
palpation.8

(sensitivity

90%)

with

SACT involves the arterial catheterization of arteries
supplying the pancreas and injecting calcium gluconate
which acts as the insulin secretagogue. The samples are
then collected from the right hepatic vein before and after
the calcium gluconate injection at diﬀerent time intervals.
The pancreatic artery showing the highest relative fold
increase (two to four times) in hepatic venous insulin
concentration over baseline following calcium stimulation
is considered to be the dominant artery supplying the
insulinoma.9 Preoperative localization of insulinoma can
guide the surgeon to decide the extent of surgery.
Since we did not have the availability of Endoscopic
ultrasound facility in our center therefore Selective Arterial
calcium Stimulation testing with hepatic venous sampling
was considered an option for tumour localization .
Despite its high sensitivity, the utility of SACT outside
insulinoma diagnosis remains unkown. Similarly the
diagnostic accuracy of this test also remains undetermined
as this test is done on patients with a pre established
diagnosis of insulinoma. The diagnostic accuracy of SACT
was questioned with diﬀusely positive SACT response in
cases of surreptious Repaglinide and sulfonylurea.12,13
Important challenge in doing SCAST is having a centre
equipped with interventional radiology services with
Interventional radiologist able to interpret normal and
abberant vascular anatomy since the anatomy of the
coeliac axis and superior mesenteric artery is aberrant in
approximately 40 percent of patients. Close
communication
between
the
endocrinologist,
interventional radiologist and laboratory is required to
Vol. 70, No. 9, September 2020

Insulinomas being rare intrapancreatic tumours can pose
a diagnostic dilemma due to its diﬃcult preoperative
localization but with the advent of newer invasive
modalities there has been a good yield in localizing them
preoperatively and thus avoiding unnecessary total
pancreatectomy.
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